Published in final edited form as:

Org Lett. 2013 January 4; 15(1): 58–61. doi:10.1021/ol303089w.

Enantioselective Synthesis of the C(1)–C(11) Fragment of Tedanolide C

Julie G. Geist, Roland Barth, and William R. Roush

Department of Chemistry, The Scripps Research Institute, Scripps Florida, 130 Scripps Way, Jupiter, Florida 33458

William R. Roush: roush@scripps.edu

Abstract

A convergent synthesis of the protected C(1)–C(11) fragment 6 of the targeted enantiomer of tedanolide C is described. The key step of the synthesis is the Felkin-Ahn addition of vinyl iodide 7 to aldehyde 8 that proceeds in 80% yield with 4:1 diastereoselectivity.

The isolation and structure determination of tedanolide C (**1**), a marine natural product isolated from a Papua New Guinea sponge of the *Ircinia* species, was reported by Ireland and co-workers in 2006.¹ Other members of the tedanolide family include tedanolide (**2**),² 13-deoxytedanolide (**3**),³ and the candidaspongolides (**4**, Figure 1).⁴ The structure and relative stereochemistry of tedanolide C (**1**) was assigned by using NMR methods and DFT calculations, but the absolute stereochemistry remains unconfirmed.¹ Tedanolide C exhibits excellent potency against HCT-116 cells (colorectal cell line), with an IC₅₀ value of 0.057 μg/mL (90 nM), and stops the growth of HCT-116 cells in the S-phase after 24 h exposure at 0.2 μg/mL.¹ It has been postulated that tedanolide C is a protein synthesis inhibitor, like its closely related congener, 13-deoxytedanolide. Surprisingly, however, the structure reported for **1** depicts the C(11)–C(23) fragment with an enantiomeric configuration (except for the epoxide) relative to other members of the tedanolide family. The C(10)–C(23) fragment has been identified as the key pharmacophoric unit of 13-deoxytedanolide.⁵ Therefore, in planning a synthesis of tedanolide C (**1**) we decided to pursue the enantiomeric structure **5** as the synthetic target (Scheme 1) in anticipation that the configuration of the C(11)–C(23) unit of tedanolide C should be the same as for the key C(10)–C(23) pharmacophore of 13-deoxytedanolide.

In 2010 our laboratory reported the synthesis of the C(15)–C(21) fragment of **5**.⁶ Kalesse *et al.* subsequently published their synthesis of the C(14)–C(23) fragment of a diastereomeric

Correspondence to: William R. Roush, roush@scripps.edu.

Supporting Information Available: Experimental procedures and copies of ¹H NMR and ¹³C NMR spectra of new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

analog of tedanolide C using a Kiyooka aldol reaction.^{7, 8} More recently still, a synthesis of the C(1)–C(12) fragment has been reported by Smith *et al.* by a route involving an asymmetric hydroformylation of a 1,3-diene.⁹ We report herein our synthesis of **6**, a protected version of the C(1)–C(11) fragment of the targeted enantiomer of tedanolide C.

Our strategy for the synthesis of fragment **6** (Scheme 1) involves the formation of the secondary C(7) hydroxyl group by addition of vinyl iodide **7** to aldehyde **8**. We anticipated that the C(7) alcohol stereochemistry would be controlled by accessing a Felkin–Ahn transition state for the carbonyl addition.¹⁰ Aldehyde **8** was synthesized starting from the known aldehyde **9**¹¹ (Scheme 2). Subjection of **9** to an enantioselective Reformatsky-type reaction¹² with oxazolidinone **10**¹³ in the presence of SnCl₂ afforded **11** in 56% yield with > 98:2 d.r. The absolute configuration of the hydroxyl group at C(3) of **11** was confirmed by using the advanced Mosher ester method.¹⁴ Protection of alcohol **11** as a TBS ether using TBSOTf and 2,6-lutidine, followed by reduction of the acyl oxazolidinone with LiBH₄ and subsequent Parish–Doering oxidation¹⁵ of the primary alcohol afforded aldehyde **12**.¹⁶ The *syn* aldol reaction between **12** and propionyl oxazolidinone **13**¹⁷ was performed in the presence of TiCl₄ and (–)-sparteine,¹⁸ and gratifyingly afforded aldol **14** in 76% yield as a single diastereomer. The use of (–)-sparteine in this reaction was essential to obtain synthetically useful diastereoselectivity; the aldol reaction of the titanium enolate generated with diisopropylethyl amine (DIPEA) as the base afforded a 1:1 mixture of diastereomers. Protection of the newly formed hydroxyl group of **14** as a TMS ether, followed by reduction of the acyl oxazolidinone with LiBH₄ and oxidation of the primary alcohol with SO₃·pyridine¹⁵ completed this synthesis of aldehyde **8**.

The stereochemistry of aldol **14** was verified by the studies summarized in Scheme 3. Alcohol **15**, obtained in two steps from **14**, was elaborated into diol **16** in 62% yield by benzylation of the primary alcohol¹⁹ and deprotection of the two silyl ethers. Analysis of the ¹³C NMR spectrum of the derived acetonide **17** using Rychnovsky's method²⁰ confirmed the *syn* relationship between C(3)-OH and C(5)-OH. Independently, acetonide **18** was also generated in two steps from alcohol **15**. The small H_a–H_b and H_a–H_c coupling constants (*J* < 2 Hz) observed in the ¹H NMR spectrum of **18** suggested that this compound adopts a chair-like conformation in which H_a is in equatorial position. Furthermore, the ¹H NOE data obtained for **18** highlighted in Scheme 3 supported the assignment of *syn* stereochemistry between C(5)-OH and C(6)-CH₃ in aldol **14**.

Vinyl iodide **7** was synthesized from alkyne **19**,²¹ which is available in 5 steps from commercial methyl (*R*)-β-hydroxyisobutyrate (Scheme 4). We considered **19** to be a useful intermediate as the protecting group for the primary hydroxyl group can be easily removed and modified. Deprotection of the *p*-methoxybenzyl (PMB) ether was accomplished by treatment of **19** with DDQ at 0 °C in a 1:1 mixture of pH 7 phosphate buffer and CH₂Cl₂. The volatile propargyl alcohol was quickly treated with dimethoxytrityl chloride (DMTrCl) to give **20** in 88% yield over these two steps. Hydrostannylation of **20** using freshly distilled Bu₃SnH proceeded in 82% yield and with 93:7 regioselectivity. Treatment of the vinylstannane with I₂ afforded vinyl iodide **7** almost quantitatively.²²

In a first attempt towards the coupling of **7** and **8**, treatment of **7** with *t*BuLi (2.2 equiv) at –78 °C, followed by addition of **8** at –78 °C provided **21** as a 1:1 ratio of diastereomers. It has been reported that vinyl zincates provide higher diastereoselectivity upon addition to chiral aldehydes than the corresponding vinyl lithium reagents.²³ Thus, as shown in Scheme 4, treatment of vinyl iodide **7** with 2.2 equiv of *t*BuLi at –78 °C for 10 min, followed by addition of 1.1 equiv of ZnMe₂ at –78 °C for 5 min afforded a solution of the vinyl zincate reagent. To this solution was added a solution of aldehyde **8** and the mixture was stirred for 3 h at –78 °C prior to workup. This procedure provided alcohol **21** in 80% yield as a 4:1

mixture of diastereomers that were not separated at this stage. The absolute configuration of the C(7) hydroxyl group of the major diastereomer was assigned by using the advanced Mosher ester method.¹⁴ Protection of the C(7) hydroxyl group of **21** as a TBS ether proceeded in 70% yield. In the next step, the DMTr protecting group was removed selectively by treatment of the fully protected intermediate with a 1:1:1 mixture of AcOH, trifluoroethanol and CH₂Cl₂ without removal of the TMS ether.²⁴ Gratifyingly, this step enabled the separation of the two C(7)-diastereomers by standard column chromatography; the major diastereomer was isolated in 62% yield from this sequence (86% b.r.s.m.). The hindered C(5)-OTMS ether protecting group was removed in a subsequent step by using a solution of 40% HCO₂H in methanol, which afforded diol **22** in 81% yield.

For the final step of the synthesis of **6**, we expected the oxidation of the very hindered C(5)-hydroxyl group to be slower than the oxidation of the primary alcohol, and were concerned that problems could arise with the β,γ -unsaturated aldehyde which in related systems is known to be sensitive towards epimerization at C(10). We selected the Dess-Martin periodinane reagent²⁴ for this step since this reagent is known to be useful for oxidations that give aldehyde products that are highly prone to epimerization when other oxidation conditions are used.²⁵ However complete oxidation of **22** could not be achieved by using 5 equiv of the Dess–Martin periodinane even when the reaction was performed for 1 h at ambient temperature. The reaction had to be gently heated to 40 °C for 20 min to drive the oxidation of the C(5) alcohol to completion. In this way, the fully protected C(1)–C(11) fragment **6** of tedanolide C was obtained as a single isomer in almost quantitative yield, with no evidence of epimerization at C(10).

In summary, we developed a diastereoselective synthesis of the protected C(1)–C(11) fragment **6** of the targeted enantiomer of tedanolide C in 13 steps starting from the known aldehyde **9**. The synthesis involves a SnCl₂ mediated enantioselective Reformatsky-type reaction to set the C(3) stereocenter, and an Evans-Crimmins aldol reaction to set the *syn* relationship between C(5) and C(6). The C(7) stereocenter was set by the Felkin-Ahn controlled addition of the vinylzincate derived from vinyl iodide **7** to aldehyde **8**. The synthesis of **6** was completed by the Dess-Martin periodinane oxidation of the C(5)–C(11) diol unit. Further progress towards completion of a synthesis of tedanolide C will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support provided by the National Institutes of Health (GM038436) is gratefully acknowledged. J. G. G. thanks the Swiss National Science Foundation (SNSF) for a postdoctoral fellowship. We also thank Dr. Souad Ouizem for proofreading the manuscript.

References

1. Chevallier C, Bugni TS, Feng X, Orendt AM, Ireland CM. J Org Chem. 2006; 71:2510. [PubMed: 16526806]
2. Schmitz FJ, Gunasekera SP, Yalamanchili G, Bilayet Hossain M, Van Der Helm D. J Am Chem Soc. 1984; 106:7251.
3. Fusetani N, Sugawara T, Matsunaga S, Hirota H. J Org Chem. 1991; 56:4971.
4. (a) Meragelman TL, Willis RH, Woldemichael GM, Heaton A, Murphy PT, Snader KM, Newman DJ, Van Soest R, Boyd MR, Cardellina JH, McKee TC. J Nat Prod. 2007; 70:1133. [PubMed:

- 17564468] (b) Whitson EL, Pluchino KM, Hall MD, McMahon JB, McKee TC. *Org Lett.* 2011; 13:3518. [PubMed: 21644548]
5. (a) Nishimura S, Matsunaga S, Yoshida M, Hirota H, Yokoyama S, Fusetani N. *Bioorg Med Chem.* 2005; 13:449. [PubMed: 15598566] (b) Nishimura S, Matsunaga S, Yoshida S, Nakao Y, Hirota H, Fusetani N. *Bioorg Med Chem.* 2005; 13:455. [PubMed: 15598567]
6. Barth R, Roush WR. *Org Lett.* 2010; 12:2342. [PubMed: 20405855]
7. Bülow L, Naini A, Fohrer J, Kalesse M. *Org Lett.* 2011; 13:6038. [PubMed: 22026452]
8. Kalesse's synthetic target has the C(10)–C(23) stereochemistry the same as our target **5**, but has C(1)–C(7) stereochemistry the same as in the originally proposed structure for tedanolide **C (1)**.
9. Smith TE, Fink SJ, Levine ZG, McClelland KA, Zackheim AA, Daub ME. *Org Lett.* 2012; 14:1452. [PubMed: 22375885]
10. (a) Cherest M, Felkin H, Prudent N. *Tetrahedron Lett.* 1968:2199.(b) Anh NT, Eisenstein O. *Nouv J Chim.* 1977; 1:61.
11. Oka T, Murai A. *Tetrahedron.* 1998; 54:1.
12. (a) Kögl M, Brecker L, Warrass R, Mulzer J. *Angew Chem Int Ed.* 2007; 46:9320.(b) Kögl M, Brecker L, Warrass R, Mulzer J. *Eur J Org Chem.* 2008:2714.
13. Kende AS, Kawamura K, Orwat MJ. *Tetrahedron Lett.* 1989; 30:5821.
14. (a) Dale JA, Mosher HS. *J Am Chem Soc.* 1973; 95:512.(b) Hoye TR, Jeffrey CS, Shao F. *Nat Protoc.* 2007; 2:2451. [PubMed: 17947986]
15. Parikh JR, von Doering EW. *J Am Chem Soc.* 1967; 89:5505.
16. Hartung IV, Niess B, Haustedt LO, Hoffmann HMR. *Org Lett.* 2002; 4:3239. [PubMed: 12227758]
17. Evans DA, Bartroli J, Shih TL. *J Am Chem Soc.* 1981; 103:2127.
18. Crimmins MT, King BW, Tabet EA, Chaudhary K. *J Org Chem.* 2001; 66:894. [PubMed: 11430110]
19. Brummond KM, Hong SP. *J Org Chem.* 2005; 70:907. [PubMed: 15675848]
20. Rychnovsky SD, Rogers B, Yang G. *J Org Chem.* 1993; 58:3511.
21. Organ MG, Wang J. *J Org Chem.* 2003; 68:5568. [PubMed: 12839448]
22. Sun X-Y, Tian X-Y, Li Z-W, Peng X-S, Wong HNC. *Chem Eur J.* 2011; 17:5874. [PubMed: 21491517]
23. (a) Hayashi Y, Shoji M, Ishikawa H, Yamaguchi J, Tamura T, Imai H, Nishigaya Y, Takabe K, Kakeya H, Osada H. *Angew Chem Int Ed.* 2008; 47:6657.(b) Marshall JA, Eidam P. *Org Lett.* 2004; 6:445. [PubMed: 14748614]
24. Matysiak S, Böldicke T, Tegge W, Frank R. *Tetrahedron Lett.* 1998; 39:1733.
24. Dess DB, Martin JC. *J Am Chem Soc.* 1991; 113:7277.
25. Myers AG, Zhong B, Movassaghi M, Kung DW, Lanman BA, Kwon S. *Tetrahedron Lett.* 2000; 41:1359.

Figure 1.
Tedanolide natural product family.

Scheme 1.
Strategy for the Synthesis of the Protected C(1)–C(11) Fragment of the Targeted Enantiomer of Tedanolide C

Scheme 2.
Synthesis of Aldehyde **8**

Scheme 3.
Stereochemical Assignments

Scheme 4.
Synthesis of the C(1)–C(11) Fragment **6** of Tedanolide C